Latest filing published 13 Jul 2022 for Prokidney CORP..
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +2.3%Entry US$28.99 · Close at T+365 US$29.67
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Uma Sinha: trading record in brief
This profile gathers the share dealings of Uma Sinha across 3 companies, led by Eidos Therapeutics, Inc., BridgeBio Pharma, Inc. and Prokidney Corp. In total, 36 filings cover trades dated from 30 November 2018 to 11 July 2022.
On the open market, the record shows 1 purchase worth €211k and 26 sales worth €3.0M. The net balance comes to €2.8M on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 5 share grants and 2 option exercises.
The newest entry dates from 13 July 2022: a share grant, in Prokidney Corp. The most recent open-market purchase was published on 3 July 2019, 2,685 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Uma Sinha
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 30,000 shares0Class A Ordinary SharesSEC:0000950103-22-012368:0
- 3,000 shares0Common StockSEC:0000899243-21-003639:0
- 303,525 sharesCommon StockSEC:0000899243-21-003639:1
- 696 shares@ US$121.112.3% of flowCommon StockSEC:0000899243-21-002179:0
- 572 shares@ US$122.271.9% of flowCommon StockSEC:0000899243-21-002179:1
- 1,498 shares@ US$123.485.0% of flowCommon StockSEC:0000899243-21-002179:2
- 4,934 shares@ US$124.7216.6% of flowCommon StockSEC:0000899243-21-002179:3
- 2,000 shares@ US$125.356.8% of flowCommon StockSEC:0000899243-21-002179:4
- 300 shares@ US$126.391.0% of flowCommon StockSEC:0000899243-21-002179:5
- 3,798 shares@ US$89.626730.6% of flowCommon StockSEC:0000899243-20-032771:0
- 702 shares@ US$90.63395.7% of flowCommon StockSEC:0000899243-20-032771:1
- 300 shares@ US$91.892.5% of flowCommon StockSEC:0000899243-20-032771:2
- 200 shares@ US$92.9651.7% of flowCommon StockSEC:0000899243-20-032771:3
- 469 sharesCommon StockSEC:0000899243-20-031549:0
- 1,300 shares@ US$71.90248.6% of flowCommon StockSEC:0000899243-20-029938:0
- 3,700 shares@ US$72.601624.8% of flowCommon StockSEC:0000899243-20-029938:1
- 69 shares@ US$52.080.3% of flowCommon StockSEC:0000899243-20-026974:0
- 100 shares@ US$52.000.5% of flowCommon StockSEC:0000899243-20-026974:1
- 4,831 shares@ US$52.354223.4% of flowCommon StockSEC:0000899243-20-026974:2
- 468 sharesCommon StockSEC:0000899243-20-022792:0
- 444 shares@ US$41.571.0% of flowCommon StockSEC:0000899243-20-015410:0
- 1,523 shares0Common StockSEC:0000899243-20-013835:0
- 9,973 shares@ US$61.6127.3% of flowCommon StockSEC:0000899243-19-029765:0
- 825 shares@ US$62.492.3% of flowCommon StockSEC:0000899243-19-029765:1
- 1,702 shares@ US$63.314.8% of flowCommon StockSEC:0000899243-19-029765:2
25 of 36 declarations
